Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting

Fifty-eight people with HIV switched to long-acting cabotegravir and rilpivirine in a real-world clinic setting had higher discontinuation rates because of virologic failure, side effects, or nonadherence compared to clinical trials. Archived proviral genotype testing before long-active cabotegravir and rilpivirine switch should be considered to reduce virologic failure risk.